AZD9829 / AstraZeneca - LARVOL DELTA

Study of AZD9829 in CD123+ Hematological Malignancies (clinicaltrials.gov) - P1/2 | N=104 | Recruiting | Sponsor: AstraZeneca | N=65 ➔ 104 | Trial completion date: Apr 2027 ➔ Jan 2027 | Trial primary completion date: Apr 2027 ➔ Jan 2027

Enrollment change • Monotherapy • Trial completion date • Trial primary completion date • Hematological Disorders • Hematological Malignancies • Oncology

Study of AZD9829 in CD123+ Hematological Malignancies (clinicaltrials.gov) - P1/2 | N=65 | Recruiting | Sponsor: AstraZeneca | Trial completion date: Aug 2026 ➔ Apr 2027 | Trial primary completion date: Aug 2026 ➔ Apr 2027

Monotherapy • Trial completion date • Trial primary completion date • Hematological Disorders • Hematological Malignancies • Oncology

AZD9829: Data from P1/2 trial (NCT06179511) for CD123-positive hematological malignancies in H2 2025 (AstraZeneca) - H1 & Q2 2024 Results

P1/2 data • Hematological Malignancies • Oncology

AZD9829 DEMONSTRATES COMBINATION BENEFIT WITH HMA AND VENETOCLAX IN AML CELL LINES, PATIENT SAMPLES AND PDX MODELS. (EHA 2024) - " In vitro: 7 AML cell lines were treated with either AZD9829, VEN, HMA (Decitabine), a double combination ofAZD9829 and VEN or HMA, or a triple combination of AZD9829 with VEN and HMA for 6 days...1µM) and HMA (Azacitidine (AZA), 0... The monotherapy treatment of AZD9829 demonstrates enhanced efficacy compared to SoC in AML patientsamples with diverse molecular alterations. Our preclinical findings also offer justification for exploringcombinations of AZD9829 with SoC drugs in the clinic to improve long-term AML patient outcomes."

Preclinical • Acute Myelogenous Leukemia • CD123 • IL3RA

Study of AZD9829 in CD123+ Hematological Malignancies (clinicaltrials.gov) - P1/2 | N=65 | Recruiting | Sponsor: AstraZeneca | Trial completion date: Dec 2025 ➔ Aug 2026 | Trial primary completion date: Dec 2025 ➔ Aug 2026

Monotherapy • Trial completion date • Trial primary completion date • Hematological Disorders • Hematological Malignancies • Oncology

AZD9829: Data from P1/2 trial (NCT06179511) for CD123-positive hematological malignancies in 2025 (AstraZeneca) - Q4 & FY2023 Results

P1/2 data • Hematological Malignancies • Oncology

Study of AZD9829 in CD123+ Hematological Malignancies (clinicaltrials.gov) - P1/2 | N=60 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting

Enrollment open • Monotherapy • Hematological Disorders • Hematological Malignancies • Oncology

Study of AZD9829 in CD123+ Hematological Malignancies (clinicaltrials.gov) - P1/2 | N=79 | Not yet recruiting | Sponsor: AstraZeneca

Monotherapy • New P1/2 trial • Hematological Disorders • Hematological Malignancies • Oncology

First Disclosure of AZD9829, a TOP1i-ADC Targeting CD123: Promising Preclinical Activity in AML Models with Minimal Effect on Healthy Progenitors (ASH 2023) - "Furthermore, AZD9829 demonstrated durable blast reduction at day 28 after the first dose with leukemic blast reduction in blood (7/13 models) and in bone marrow (5/13 models). Safety studies in cynomolgus monkey support the clinical development of AZD9829, a promising therapeutic candidate for the treatment of AML across the spectrum of CD123-expression and genetic mutations."

Preclinical • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology • CD123 • CD33 • IL3RA

AstraZeneca advances scientific leadership in haematology at ASH 2023 (AstraZeneca Press Release) - "Updated Phase I data for AstraZeneca’s CD19/CD3 T-cell engager, AZD0486, will further demonstrate the acceptable safety profile and high response rate of this treatment in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL). We will also present the first clinical data on sabestomig, a PD-1/TIM-3 targeting bispecific antibody, in R/R Hodgkin lymphoma, showing encouraging early signals of activity. The first preclinical data for AZD9829, a novel CD123-targeting ADC, using AstraZeneca’s proprietary linker technology to deliver a topoisomerase I inhibitor warhead, will demonstrate promising anti-tumour activity in acute myeloid leukaemia. In addition, preclinical data will demonstrate anti-tumour activity of AstraZeneca’s novel PRMT5 inhibitor in MTAP silenced Hodgkin lymphoma models."

P1 data • Preclinical • Acute Myelogenous Leukemia • Hematological Malignancies • Hodgkin Lymphoma • Non-Hodgkin’s Lymphoma • Oncology